β-Amyloid induced effects on cholinergic, serotonergic, and dopaminergic neurons is differentially counteracted by anti-inflammatory drugs

Journal of Neuroscience Research

Volumn 91, Issue 1, 2013, Pages 83-94

  Hochstrasser, Tanja ^a   Hohsfield, Lindsay A ^a   Sperner Unterweger, Barbara ^a   Humpel, Christian ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

amyloid; Anti inflammatory drugs; Brain slice; Inflammation

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; ANTIINFLAMMATORY AGENT; CELECOXIB; CHOLINE ACETYLTRANSFERASE; CITALOPRAM; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; INDOMETACIN; PICLAMILAST; TRYPTOPHAN HYDROXYLASE; TYROSINE 3 MONOOXYGENASE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN SLICE; CELL VIABILITY; CHOLINERGIC NERVE CELL; CONTROLLED STUDY; CYTOKINE RELEASE; DEPRESSION; DOPAMINERGIC NERVE CELL; DORSAL RAPHE NUCLEUS; IMMUNOHISTOCHEMISTRY; MESENCEPHALON; MEYNERT BASAL NUCLEUS; NERVE CELL DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SEROTONINERGIC NERVE CELL; WESTERN BLOTTING;

AMYLOID BETA-PEPTIDES; ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; BLOTTING, WESTERN; BRAIN; CHOLINERGIC NEURONS; DOPAMINERGIC NEURONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; NERVE DEGENERATION; ORGAN CULTURE TECHNIQUES; RATS; RATS, SPRAGUE-DAWLEY; SEROTONERGIC NEURONS;

EID: 84869176950     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23126     Document Type: Article

References (66)

1. Arzt E, Costas M, Finkielman S, Nahmod VE. 1991. Serotonin inhibition of tumor necrosis factor-alpha synthesis by human monocytes. Life Sci 48: 2557-2562.
2. Asanuma M, Nishibayashi-Asanuma S, Miyazaki I, Kohno M, Ogawa N. 2001. Neuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals. J Neurochem 76: 1895-1904.
3. Atwood CS, Obrenovich ME, Liu T, Chan H, Perry G, Smith MA, Martins RN. 2003. Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta. Brain Res Brain Res Rev 43: 1-16.
4. Ballmaier M, Narr KL, Toga AW, Elderkin-Thompson V, Thompson PM, Hamilton L, Haroon E, Pham D, Heinz A, Kumar A. 2008. Hippocampal morphology and distinguishing late-onset from early-onset elderly depression. Am J Psychiatry 165: 229-237.
5. Bannwarth B, Lapicque F, Pehourcq F, Gillet P, Schaeverbeke T, Laborde C, Dehais J, Gaucher A, Netter P. 1995. Stereoselective disposition of ibuprofen enantiomers in human cerebrospinal fluid. Br J Clin Pharmacol 40: 266-269.
6. Chen H, Zhang SM, Hernán MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE, Ascherio A. 2003. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 60: 1059-1064.
7. Choi SH, Bosetti F. 2009. Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid. Aging 1: 234-244.
8. Crow TJ, Cross AJ, Cooper SJ, Deakin JF, Ferrier IN, Johnson JA, Joseph MH, Owen F, Poulter M, Lofthouse R. 1984. Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides. Neuropharmacology 23: 1561-1569.
9. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE. 1998. Cyclooxygenase in biology and disease. FASEB J 12: 1063-1073.
10. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, Ozols VV, Jessing KW, Zavitz KH, Koo EH, Golde TE. 2003. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 112: 440-449.
11. 1-42 and Abeta25-35 toxicity in organotypic hippocampal slice cultures. Neurochem Res 34: 295-303.
12. Gasparini L, Ongini E, Wenk G. 2004a. Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action. J Neurochem 91: 521-536.
13. Gasparini L, Rusconi L, Xu H, del Soldato P, Ongini E. 2004b. Modulation of beta-amyloid metabolism by non-steroidal anti-inflammatory drugs in neuronal cell cultures. J Neurochem 88: 337-348.
14. Gonzalo-Ruiz, Gonzalez I, Sanz-Anquela JM. 2003. Effects of β-amyloid protein on serotoninergic, noradrenergic, and cholinergic markers in neurons of the pontomesencephalic tegmentum in the rat. J Chem Neuroanat 26: 153-169.
15. Haass C, Selkoe DJ. 2007. Soluble protein oligomers in Biomarkers in Alzheimer's disease degeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8: 101-112.
16. Hochstrasser T, Ullrich C, Sperner-Unterweger B, Humpel C. 2011. Inflammatory stimuli reduce survival of serotonergic neurons and induce neuronal expression of indoleamine 2, 3-dioxygenase in rat dorsal raphe nucleus organotypic brain slices. Neuroscience 184: 128-138.
17. Hohsfield LA, Humpel C. 2010. Homocysteine enhances transmigration of rat monocytes through a brain capillary endothelial cell monolayer via ICAM-1. Curr Neurovasc Res 7: 192-200.
18. Hollis JH, Evans AK, Bruce KP, Lightman SL, Lowry CA. 2006. Lipopolysaccharide has indomethacin-sensitive actions on Fos expression in topographically organized subpopulations of serotonergic neurons. Brain Behav Immun 20: 569-577.
19. Imbimbo BP. 2009. An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease. Expert Opin Invest Drugs 18: 1147-1168.
20. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wölfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Götz J. 2010. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 142: 387-397.
21. Iwata Y, Nicole O, Zurakowski D, Okamura T, Jonas RA. 2010. Ibuprofen for neuroprotection after cerebral ischemia. J Thorac Cardiovasc Surg 139: 489-493.
22. Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM, Coppola D, Morgan D, Gordon MN. 2002. Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 22: 2246-2254.
23. Jarosik J, Legutko B, Unsicker K, von Bohlen Und Halbach O. 2007. Antidepressant-mediated reversal of abnormal behavior and neurodegeneration in mice following olfactory bulbectomy. Exp Neurol 204: 20-28.
24. Kaufmann WE, Andreasson KI, Isakson PC, Worley PF. 1997. Cyclooxygenases and the central nervous system. Prostaglandins 54: 601-624.
25. Kocki T, Wnuk S, Kloc R, Kocki J, Owe-Larsson B, Urbanska EM. 2011. New insight into the antidepressants action: modulation of kynurenine pathway by increasing the kynurenic acid/3-hydroxykynurenine ratio. J Neural Transm [E-pub ahead of print].
26. Kummer MP, Hülsmann C, Hermes M, Axt D, Heneka MT. 2012. Nitric oxide decreases the enzymatic activity of insulin degrading enzyme in APP/PS1 mice. J Neuroimmune Pharmacol [E-pub ahead of print].
27. Lai AY, McLaurin J. 2012. Clearance of amyloid-β by microglia and macrophages: the issue of what, when and where. Future Neurol 7: 165-176.
28. Leonard BE. 2001. Changes in the immune system in depression and dementia: causal or co-incidental effects? Int J Dev Neurosci 19: 305-312.
29. Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe KH, Frautschy SA, Cole GM. 2000. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 20: 5709-5714.
30. Maccioni RB, Rojo LE, Fernández JA, Kuljis RO. 2009. The role of neuroimmunomodulation in Alzheimer's disease. Ann N Y Acad Sci 1153: 240-246.
31. Maes M. 1999. Major depression and activation of the inflammatory response system. Adv Exp Med Biol 461: 25-46.
32. Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, Kubera M, Bob P, Lerer B, Maj M. 2009. The inflammatory and neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 24: 27-53.
33. Manelli AM, Puttfarcken PS. 1995. Beta-amyloid-induced toxicity in rat hippocampal cells: in vitro evidence for the involvement of free radicals. Brain Res Bull 38: 569-576.
34. Marchesi VT. 2011. Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy. FASEB J 25: 5-13.
35. Marksteiner J, Kemmler G, Weiss EM, Knaus G, Ullrich C, Mechtcheriakov S, Oberbauer H, Auffinger S, Hinterhölzl J, Hinterhuber H, Humpel C. 2011. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 32: 539-540.
36. Matoga M, Péhourcq F, Lagrange F, Tramu G, Bannwarth B. 1999. Influence of molecular lipophilicity on the diffusion of arylpropionate non-steroidal anti-inflammatory drugs into the cerebrospinal fluid. Arzneimittelforschung 49: 477-482.
37. McCluskie K, Klein U, Linnevers C, Ji YH, Yang A, Husfeld C, Thomas GR. 2006. Phosphodiesterase type 4 inhibitors cause proinflammatory effects in vivo. J Pharmacol Exp Ther 319: 468-476.
38. McGeer PL, McGeer EG. 2004. Inflammation and the degenerative diseases of aging. Ann N Y Acad Sci 1035: 104-116.
39. Moghaddam HF, Hemmati A, Nazari Z, Mehrab H, Abid KM, Ardestani MS. 2007. Effects of aspirin and celecoxib on rigidity in a rat model of Parkinson's disease. Pak J Biol Sci 10: 3853-3858.
40. Moon M, Kim HG, Hwang L, Seo JH, Kim S, Hwang S, Kim S, Lee D, Chung H, Oh MS, Lee KT, Park S. 2009. Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation. Neurotox Res 15: 332-347.
41. Murgas P, Godoy B, von Bernhardi R. 2012. Aβ potentiates inflammatory activation of glial cells induced by scavenger receptor ligands and inflammatory mediators in culture. Neurotox Res [E-pub ahead of print].
42. Nagele RG, Wegiel J, Venkataraman V, Imaki H, Wang KC, Wegiel J. 2004. Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease. Neurobiol Aging 25: 663-674.
43. Nath S, Agholme L, Kurudenkandy FR, Granseth B, Marcusson J, Hallbeck M. 2012. Spreading of neurodegenerative pathology via neuron-to-neuron transmission of β-amyloid. J Neurosci 32: 8767-8777.
44. Nitsch RM, Deng M, Growdon JH, Wurtman RJ. 1996. Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion. J Biol Chem 271: 4188-4194.
45. Olanow CW, Tatton WG. 1999. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 22: 123-144.
46. Parihar MS, Brewer GJ. 2010. Amyloid-β as a modulator of synaptic plasticity. J Alzheimers Dis 22: 741-763.
47. Pasinetti GM. 2002. From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer's disease: the role of NSAIDs and cyclooxygenase in beta-amyloidosis and clinical dementia. J Alzheimers Dis 4: 435-445.
48. Price JM, Chi X, Hellermann G, Sutton ET. 2001. Physiological levels of beta-amyloid induce cerebral vessel dysfunction and reduce endothelial nitric oxide production. Neurol Res 23: 506-512.
49. Rapp MA, Schnaider-Beeri M, Purohit DP, Perl DP, Haroutunian V, Sano M. 2008. Increased neurofibrillary tangles in patients with Alzheimer disease with comorbid depression. Am J Geriatr Psychiatry 16: 168-174.
50. Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, Evert BO, Dumitrescu-Ozimek L, Thal DR, Landreth G, Walter J, Klockgether T, van Leuven F, Heneka MT. 2006. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A 103: 443-448.
51. Schatz DS, Kaufmann WA, Saria A, Humpel C. 1999. Dopamine neurons in a simple GDNF-treated meso-striatal organotypic coculture model. Exp Brain Res 127: 270-278.
52. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. 2007. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27: 2866-2875.
53. Shi M, Zhang J. 2011. CSF α-synuclein, tau, and amyloid β in Parkinson's disease. Lancet Neurol 10: 681.
54. Szczepanik AM, Rampe D, Ringheim GE. 2001. Amyloid-beta peptide fragments p3 and p4 induce pro-inflammatory cytokine and chemokine production in vitro and in vivo. J Neurochem 77: 304-317.
55. Tuppo EE, Arias HR. 2005. The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol 37: 289-305.
56. Ullrich C, Pirchl M, Humpel C. 2010. Hypercholesterolemia in rats impairs the cholinergic system and leads to memory deficits. Mol Cell Neurosci 45: 408-417.
57. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH. 2001. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414: 212-216.
58. Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Ozols V, Fauq A, Golde TE, Koo EH. 2003. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J Biol Chem 278: 31831-31837.
59. Weis C, Marksteiner J, Humpel C. 2001. Nerve growth factor and glial cell line-derived neurotrophic factor restore the cholinergic phenotype in organotypic brain slice of the basal nucleus of Meynert. Neuroscience 102: 129-138.
60. White JA, Manelli AM, Holmberg KH, Van Eldik LJ, Ladu MJ. 2005. Differential effects of oligomeric and fibrillar amyloid-β-1-42 on astrocyte-mediated inflammation. Neurobiol Dis 18: 459-465.
61. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. 1982. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 215: 1237-1239.
62. Whitton PS. 2007. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 150: 963-976.
63. Xiao L, O'Callaghan JP, O'Donnell JM. 2011. Effects of repeated treatment with phosphodiesterase-4 inhibitors on cAMP signaling, hippocampal cell proliferation, and behavior in the forced-swim test. J Pharmacol Exp Ther 338: 641-647.
64. Zassler B, Dechant G, Humpel C. 2005. Urea enhances the nerve growth factor-induced neuroprotective effect on cholinergic neurons in organotypic rat brain slices. Neuroscience 130: 317-323.
65. Zhang HT, Zhao Y, Huang Y, Deng C, Hopper AT, De Vivo M, Rose GM, O'Donnell JM. 2006. Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats. Psychopharmacology 186: 209-217.
66. Zhu X, Raina AK, Lee HG, Casadesus G, Smith MA, Perry G. 2004. Oxidative stress signalling in Alzheimer's disease. Brain Res 1000: 32-39.